Skin Conditions & Dermatology Clinical Trials Update: Week 17, 2026

Published April 24, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

This Phase 3 study is testing two different doses of Amlitelimab, a new medicine for people aged 12 and older with moderate-to-severe atopic dermatitis. The goal is to see if Amlitelimab can help control symptoms and reduce flare-ups over time. Results are expected after up to 68 weeks, and if positive, this treatment could offer a new way to manage this often challenging skin condition.

A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

This ongoing Phase 3 trial is testing baricitinib, an oral medication, in children aged 6 to under 18 with severe alopecia areata, an autoimmune disease causing hair loss. If effective and safe, baricitinib could provide a new option to help children reduce hair loss and improve hair regrowth. The study is currently recruiting at multiple sites worldwide and includes long-term follow-up to understand lasting effects.

Minoxidil for Treating White Hair: A Randomized Controlled Trial

This Phase 4 trial evaluated topical Minoxidil as a treatment for adults with grey hair not caused by illness. Conducted in China, the study included 141 participants aged 18 to 65. Results are pending, but if successful, this could be a new option for people looking to restore natural hair color and address cosmetic concerns related to greying hair.

Bimekizumab in Plaque Psoriasis

This study focused on bimekizumab, a biologic treatment for adults with moderate to severe plaque psoriasis who have not responded well to other therapies. Completed in the United States, the trial aims to assess safety and effectiveness for patients who have struggled with previous interleukin-targeted treatments. Pending results may provide hope for better treatment options in difficult cases of psoriasis.

Tirbanibulin for Pediatric Warts

This Phase 4 trial is testing tirbanibulin ointment as a treatment for hand warts in children. Warts can be persistent and uncomfortable, and this study is looking at a new topical option that may be easier to use and better tolerated than existing treatments. The trial is currently recruiting in the United States and focuses on improving care for pediatric patients with hand warts.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.